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Dear Editor,
Hepatitis B virus (HBV) is a unique DNA virus that repli-
cates via pre-genomic RNA.1 According to current estimates,
approximately 4 million individuals living with HIV world-
wide have chronic hepatitis B (CHB).2 For the treatment of
HBV/HIV co-infected patients, several guidelines recommend
the use of nucleos(t)ide analogues (NA), such as a com-
bined lamivudine (LAM) and tenofovir (TDF) therapy.3 During
long-term NA therapy, drug-resistant mutations emerge,
resulting in an increase of HBV-DNA expression. During LAM
therapy, the most classical mutations are observed in the
tyrosine-methionine-aspartate-aspartate (YMDD) motif of the
HBV-DNA polymerase at reverse transcriptase domain.3 Low
HBV-DNA load in serum may hamper the detection of drug
resistance mutations in HBV/HIV co-infected patients. Serum
HBV-RNA can be found during LAM therapy and it can be
detected when HBV-DNA is undetectable. The objectives of
this study were to evaluate HBV-RNA detection in serum of
HBV/HIV co-infected patients under antiviral treatment and
to detect the early emergence of LAM resistance mutations
by pyrosequencing. Ten CHB male patients were enrolled in
this study and divided into three groups: I- six HBV/HIV co-
infected patients treated with LAM and TDF for one year (M1
and 2429); three and ﬁve years (1181 and 3013), and ten years
(3107 and 1452); II- two HBV monoinfected naïve patients;
and III- two HBV/HIV co-infected naïve patients. Serum sam-
ples collected from enrolled patients who provided written
informed consent were obtained and stored at -80 ◦C. This
Table 1 – Detection of LAM resistance mutations by direct sequ
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HBV-RNA
Direct  sequencing 
Pyrosequencing 
HBV-DNA
Direct sequencing 
Pyrosequencing encing
study was approved by the ethical committee of Oswaldo
Cruz Foundation with ref. no. 575/10. Serum samples were
tested for HBsAg and HBeAg by a commercial immunoassay
BioELISA HBsAg colour, Biokit (Barcelona, Spain) and DiaSorin
ETI-EBK PLUS (Vercelli, Italy) respectively, according to the
manufacturer’s instructions. Total nucleic acid was extracted
using the High Pure Viral Nucleic Acid kit (Roche, Konzern-
Hauptsitz, Switzerland) that allows simultaneous detection
of DNA and RNA, according to the manufacturer’s instruc-
tions. For HBV-DNA detection, small S region was ampliﬁed
by a semi-nested PCR assay that ampliﬁes HBV genotypes A-
H.4 For HBV-RNA detection, a RT-PCR using the Superscript
III one-step RT-PCR kit (Invitrogen, Carlsbad, CA) was carried
out, amplifying the preS/S region. cDNA synthesis was per-
formed by real-time PCR using M-MLV RT (Promega Corp.,
Madison, WI,  USA) according to the manufacturer’s instruc-
tions. Phylogenetic analysis identiﬁed HBV genotypes A and
D. Pyrosequencing of a fragment of the HBV polymerase
gene, containing the YMDD motif, was performed according
to a previously described procedure5 using PyroMark Q96 ID
(QIAGEN Valencia, CA, USA). This pyrosequencing assay was
accurate for detecting mutations in minor subpopulations as
low as 5% of the total. HBV-DNA and HBV-RNA (cDNA) viral
loads were determined by real-time PCR. HBV-DNA and/or
RNA were detected in serum samples from 4/6 HBV/HIV co-encing and pyrosequencing.
M1 2429 1181
YMDD YMDD YVDD
YMDD (94%)
YIDD (6%)
YMDD  YMDD (30%)
YVDD (70%)
YMDD YMDD YVDD
YMDD (96%)
YIDD (4%)
YMDD  YVDD
higher than the HBV-DNA. M204 V/I resistance mutation was
investigated in HBV-DNA and/or HBV-RNA and mixtures of
wild type and mutant populations were detected (Table 1).
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BV-RNA can be a useful tool for monitoring the emergence
f drug resistance mutations in HBV/HIV co-infected patients
nder antiviral treatment.
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